Overview

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Pfizer
Treatments:
Ertugliflozin